Etigilimab

DRUG2 trials

Sponsors

Mereo BioPharma, M.D. Anderson Cancer Center

Conditions

Advanced Solid TumorMetastatic Solid TumorOvarian CancerSolid Tumor, Adult

Phase 1

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

CompletedNCT04761198

Mereo BioPharmaAdvanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor, Adult

Start: 2021-03-23End: 2023-10-30Updated: 2025-03-17

Phase 2

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Active, not recruitingNCT05715216

M.D. Anderson Cancer CenterOvarian Cancer

Start: 2021-10-01End: 2027-02-08Updated: 2026-07-08

Related Papers

EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.

Journal of Clinical Oncology2025-05-28

Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors.

Journal of Clinical Oncology2022-06-013 citations